Total liabilities · 2024–2025
Nasus Pharma total liabilities
$2.2M−43.1% · FY2025
Nasus Pharma (NSRX) reported $2.2M in total liabilities for fiscal 2025, −43.1% year on year.
Total liabilities — Total liabilities is everything the company owes at the balance-sheet date — debt, payables, deferred revenue and provisions together. Where a filer does not tag it, we calculate it as total assets minus total equity and label the figure as calculated.
Every row links to its own SEC filing · Fiscal year 2025 · Data as of September 25, 2026 · 2024–2025 compound annual growth −43.1%
Total liabilities at companies of similar size
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Nasus Pharma total liabilities |url=https://companiesranked.com/en/company/nasus-pharma/total-liabilities |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Nasus Pharma total liabilities. CompaniesRanked. https://companiesranked.com/en/company/nasus-pharma/total-liabilitiesBibTeX
@misc{companiesranked-en-company-nasus-pharma-total-liabilities-2026,
author = {{CompaniesRanked}},
title = {{Nasus Pharma total liabilities}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/nasus-pharma/total-liabilities}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 20-F · 0001493152-26-012559 · March 25, 2026
{{cite web |title=Nasus Pharma total liabilities — 20-F (0001493152-26-012559) |url=https://www.sec.gov/Archives/edgar/data/2029039/000149315226012559/form20-f.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-03-25}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.